NCT07258745CompletedPhase 1
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 25 Aug 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 213 (actual)
- First submitted
- 3 Jul 2025
- Start date
- 11 Nov 2025
- Lead sponsor
- Chong Kun Dang Pharmaceutical Corp.
- Diseases
- Psoriasis, Ulcerative colitis, Psoriatic arthritis
- EU CT number
- 2025-522345-21-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 213
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MTZ Clinical Research powered by Pratia Coordinator of this site? Confirm its status | Warsaw | Poland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.